Conference Coverage

Novel antifungal had favorable safety, efficacy profile for onychomycosis in phase IIB study


 

AT AAD 17

– A novel orally administered antifungal showed a favorable safety and efficacy profile in the treatment of distal lateral subungual onychomycosis, in a phase IIB study presented at the annual meeting of the American Academy of Dermatology.

In the RENOVATE (Restoring Nail: An Oral VT-1161 Tablet Evaluation) study, a randomized, double-blind, placebo-controlled, dose-ranging trial, 259 adults with moderate to severe distal lateral subungual onychomycosis of the large toenail were assigned to either one of four treatment arms. They were given the antifungal, currently named VT-1161, a selective CYP51 inhibitor, at doses of 300 mg or 600 mg once weekly for 10 or 22 weeks, after receiving daily loading doses for the initial 2 weeks. The trial evaluated two dose levels of VT-1161 (300 mg and 600 mg) administered once weekly for either 10 or 22 weeks following an initial 2-week, once-daily loading dose period.

At baseline, the average involvement of the large toenail was 46%, with an average of 4.6 toenails affected. In the intent-to-treat analysis, at 48 weeks, complete cure rates in the four study drug arms ranged from 32% to 42%, compared with 0% in the placebo arm.

Amir Tavakkol, PhD, chief development officer at Viamet Pharmaceuticals, which is developing VT01161, presented the study findings during a late breaking clinical session at the meeting.

Adverse event rates and discontinuation rates were comparable to placebo through week 60, with no patients discontinuing due to any laboratory abnormalities. Nausea and muscle spasms were the most commonly reported adverse events, which Dr. Tavakkol said seemed to occur in patients given the higher doses. VT-1161 is also being studied for treatment of vulvovaginal candidiasis. In October 2016, the FDA granted the drug Qualified Infectious Disease Product and Fast Track designations for the treatment of recurrent vulvovaginal candidiasis, according to the company.

Viamet sponsored the study and Dr. Tavakkol is an employee of the company.

On Twitter @whitneymcknight

Recommended Reading

U.S. flu activity continues to decline
MDedge Internal Medicine
How to ‘de-label’ penicillin allergies in the hospital
MDedge Internal Medicine
HCV ‘cure’ within the VA appears likely
MDedge Internal Medicine
HIV research update: Late February 2017
MDedge Internal Medicine
Survey finds chronic rhinosinusitis common, burdensome
MDedge Internal Medicine
U.S. influenza activity remains steady
MDedge Internal Medicine
HIV vaccine could prevent 30 million cases by 2035
MDedge Internal Medicine
Dexmedetomidine improves sedation in sepsis
MDedge Internal Medicine
Shingles vaccine deemed effective in people with autoimmune disease
MDedge Internal Medicine
Hepatitis Outlook: Late February 2017
MDedge Internal Medicine